Celyad Oncology is a clinical-stage biopharmaceutical company focused on the development of cell-based therapies for the treatment of cancer. Co.'s clinical drug product candidates include the autologous cell therapies CYAD-01 and CYAD-02 for the treatment of relapsed / refractory acute myeloid leukemia and the allogeneic, or off-the-shelf, cell therapy CYAD-101 for the treatment of metastatic colorectal cancer. All three candidates incorporate the receptor NKG2D, an activating receptor from Natural Killer (NK) cells as the chimeric antigen receptor transduced on T-lymphocytes. NK cells are lymphocytes of the immune system that kill diseased cells. The CYAD stock yearly return is shown above.
The yearly return on the CYAD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYAD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|